Access Vascular was Founded to Transform Vascular Access.

Our company was founded to solve the significant yet unmet needs in vascular access. After shadowing physicians and learning about the challenge that thrombosis presents to vascular access, our founders set off to develop a new, groundbreaking biomaterial that is fundamentally different than the polyurethane used in conventional vascular catheters. Our foundationally unique, thrombus-evading catheters alleviate the clinical and economic burden from vascular access complications, so focus can remain on outcomes.

In 2018, we secured FDA clearance on our first product, a peripherally inserted central catheter (PICC) which was found to be effective in reducing thrombosis accumulation. In 2021, we received our second FDA clearance with the HydroMID a peripherally inserted midline catheter which has demonstrated 6x fewer complications then a standard polyurethane catheter.**

We are a privately held company based in Billerica, MA. Our headquarters consists of a 40,000 square foot facility that includes state-of-the-art laboratory and manufacturing spaces. We employ approximately 40 employees and our products are commercially available in the United States.

*Data on file at Access Vascular. Reduction of thrombus accumulation was evaluated using in vitro and in vivo models. Pre-clinical in vitro/in vivo evaluations do not necessarily predict clinical performance with respect to thrombus formation. **Bunch, J. (2022). A Retrospective Assessment of Peripheral Catheter Failures Focusing on Catheter Composition. J. Infus Nurs. Sept/Oct 2022